Medicine fell foul of regulators despite helping patients, as it required large dose. Now, Technion's pinpoint delivery system cuts quantity needed, allowing revival of drug

aMoon fund, a health-tech fund, makes a $5 million investment in venture set up by Technion's Marcelle Machluf to commercialize tumor-busting technology

Marcelle Machluf, child of a Moroccan immigrant who couldn't read or write, is seeking investors for what could be a revolutionary tumor drug-delivery platform